Disease-modifying antirheumatic drug use in the treatment of juvenile idiopathic arthritis: a cross-sectional analysis of the CARRA Registry.
Disease-modifying antirheumatic drug use in the treatment of juvenile idiopathic arthritis: a cross-sectional analysis of the CARRA Registry.
复制标题
疾病改良的抗疾病药物在治疗少年特发性关节炎中的使用：CARRA注册中心的横断面分析。
DOI：
10.3899/jrheum.120110
复制
发表时间：
2012-09
期刊：
影响因子：
--
通讯作者：
CARRA Registry Investigators
中科院分区：
文献类型：
--
作者：
Beukelman T;Ringold S;Davis TE;DeWitt EM;Pelajo CF;Weiss PF;Kimura Y;CARRA Registry Investigators
描述美国青少年特发性关节炎（JIA）儿童使用疾病缓解抗风湿药（DMARD）的特征，并确定与药物使用相关的患者因素。我们分析了2010年5月至2011年5月儿童关节炎和风湿病研究联盟（CARRA）登记处的JIA儿童横断面基线招募数据。包括当前和既往用药。我们使用简约的后向逐步logistic回归模型计算比值比（OR），以估计临床患者因素与药物使用之间的关联。我们从51个美国临床试验机构中确定了2，748名JIA儿童，中位病程为3.9年。总体而言，2，023人（74%）曾接受过非生物DMARD，1，246人（45%）曾接受过生物DMARD。在无全身性关节炎的儿童中，使用甲氨蝶呤与葡萄膜炎（OR 5.2; 95%置信区间[3.6-7.6]）、环瓜氨酸肽抗体（4.5 [1.7-12]）和广泛性少关节炎（4.1 [2.5-6.6]）的相关性最强。在无全身性关节炎的儿童中，生物制剂DMARD的使用与类风湿因子阳性（RF+）多发性关节炎（4.3 [2.9-6.6]）、银屑病关节炎（3.0 [2.0-4.4]）和葡萄膜炎（2.8 [2.1-3.7]）的相关性最强。在患有全身性关节炎的儿童中，160例（65%）曾接受过生物DMARD治疗; TNF抑制剂的使用与多发性关节炎相关（2.5 [3.8-16]），而IL-1抑制剂的使用与多发性关节炎无关。在CARRA登记研究中，大约四分之三的JIA儿童接受了非生物制剂DMARD。近一半的人接受生物DMARD治疗，其使用与类风湿因子阳性的多发性关节炎、银屑病关节炎、葡萄膜炎和全身性关节炎密切相关。
To characterize disease modifying anti-rheumatic drug (DMARD) use for children with juvenile idiopathic arthritis (JIA) in the United States and determine patient factors associated with medication use. We analyzed cross-sectional baseline enrollment data from the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry from May 2010 through May 2011 for children with JIA. Current and prior medication use was included. We used parsimonious backward stepwise logistic regression models to calculate odds ratios (OR) to estimate associations between clinical patient factors and medication use. We identified 2,748 children with JIA with a median disease duration of 3.9 years from 51 U.S. clinical sites. Overall, 2,023 (74%) had ever received a non-biologic DMARD and 1,246 (45%) had ever received a biologic DMARD. Among children without systemic arthritis, methotrexate use was most strongly associated with uveitis (OR 5.2; 95% confidence interval [3.6–7.6]), cyclic citrullinated peptide antibodies (4.5 [1.7–12]), and extended oligoarthritis (4.1 [2.5–6.6]). Among children without systemic arthritis, biologic DMARD use was most strongly associated with rheumatoid factor positive (RF+) polyarthritis (4.3 [2.9–6.6]), psoriatic arthritis (3.0 [2.0–4.4]), and uveitis (2.8 [2.1–3.7]). Among children with systemic arthritis, 160 (65%) ever received a biologic DMARD; TNF inhibitor use was associated with polyarthritis (2.5 [3.8–16]) while IL-1 inhibitor use was not. Approximately three-quarters of all children with JIA in the CARRA Registry received non-biologic DMARDs. Nearly one-half received biologic DMARDs, and their use was strongly associated with rheumatoid factor positive polyarthritis, psoriatic arthritis, uveitis, and systemic arthritis.
登录
查看更多内容
影响因子：
158.5
作者：
Silverman, E;Mouy, R;Strand, V
通讯作者：
Strand, V
影响因子：
27.4
作者：
Ruperto, Nicolino;Lovell, Daniel J.;Giannini, Edward H.
通讯作者：
Giannini, Edward H.
影响因子：
5.5
作者：
Heiligenhaus, A.;Niewerth, M.;Minden, K.
通讯作者：
Minden, K.
影响因子：
--
作者：
Ruperto, N;Murray, KJ;Martini, A
通讯作者：
Martini, A
影响因子：
--
作者：
Ruperto, Nicolino;Lovell, Daniel J.;Giannini, Edward H.
通讯作者：
Giannini, Edward H.